TrialCancer medicine2025

Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma.

Niels W C J van de Donk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.